Hourly refreshTue, Oct 27, 2026

Press Release Database

Recent press releases, indexed by topic.
Topic

Biotech & pharma

2,266 press releases in English indexed under biotech & pharma.

Clear all filters
Keywords, dates and language
Sources
up to 10
Newswires (50)
Company newsrooms (91)
Companies
Releases linked to any of up to 10 companies
AllFinanceCryptoAISaaSHealthcareReal estateEnergyRetailAutomotiveGamingMediaEducation
+ 33 more topics
DownloadExcelTXT
SaaS · Healthcare

Mental Health Screening Month: How Tech Is Fixing Therapy’s First-Month Dropout Problem

Mental Health Screening Month: How Tech Is Fixing Therapy’s First-Month Dropout Problem Mon, 10/12/2026 - 15:35 Body Every week, millions of people sit down with their mental health therapy provider, take a deep breath, and try to answer a deceptively simple question: “So, how was your week?” For many, answering that question feels like trying to reconstruct a faded memory. The intense anxiety felt while sitting in traffic on Tuesday or the sudden wave of overwhelm on Thursday evening has lost its sharp edges by Monday morning. Clients often spend the first 15 minutes of a 50-minute appointment trying to recap past events rather than diving into meaningful healing work. This disconnect between weekly visits is a major contributor to a quiet crisis in mental healthcare: one in four clients discontinue psychotherapy, most after a single session. At the same time, the market has been flooded with thousands of standalone consumer wellness apps, with research showing that roughly 89% - 92% of mental health applications are abandoned by clients. The reason is simple: self-guided algorithms can’t replace the trust, empathy and safety of a human therapist. Image Why Do Standalone Apps Fail Where Clinician-Guided Tools Succeed? Unlike standalone apps that ask users to navigate their mental health journeys alone, next-generation platforms are designed to operate directly within existing clinical practices. By keeping the mental healthcare provider at the center of the care journey, technology transforms from a passive self-help tool into an active bridge between sessions. Exemplifying this shift is ReliefAI Health, a digital health venture created through LG NOVA (the North American Innovation Center for LG Electronics), exemplifies this shift. ReliefAI is built as a digital cognitive behavioral therapy (CBT) platform, for providers and clients.   The mobile app enables clients to engage with their care plan daily and capture their mental state throughout their week.  This gives providers the ability to understand what is going on with their clients at those crucial times to be better able to assess and support their clients through the therapy process.  Rather than relying on paper notebooks or delayed memory, clients can use voice-journaling features while emotional experiences are still raw, work with interactive CBT exercises, complete clinical assessments and capture real-time mood patterns on their own schedule. How Does Between-Session Tracking Turn Passive Time Into Active Care? When technology integrates seamlessly into a clinic’s electronic health records system, the impact on care continuity is profound. "We see a crucial opportunity for technology to transform mental healthcare by strengthening the vital relationship between therapists and their clients," says the head of LG NOVA Sokwoo Rhee, Executive Vice President of Innovation at LG Electronics. "ReliefAI answers that need." Instead of starting an appointment with a blank slate, clinicians can review synthesized, objective data beforehand—observing mood trends, completed assessments and key themes from voice entries. Mental health providers begin the session already informed, bypassing routine recaps to focus immediately on deeper therapeutic progress. Rhee says this continuous model provides several distinct advantages for both clients and providers: Keeping clients connected to their therapeutic goals throughout the week can significantly reduce early dropout rates and help individuals stay committed through the critical first month. Tracking real-time insights that allow providers to tailor treatment plans dynamically and show clients tangible evidence of their growth over time. Remote therapeutic monitoring frameworks give practices structured clinical documentation and continuous engagement capabilities. What Does a Human-Centered Future for Mental Healthcare Look Like? As National Depression & Mental Health Screening Month highlights the growing demand for accessible, effective care, the narrative around digital health is evolving. The future of mental healthcare does not belong to standalone algorithms or automated substitutes for human connection, according to Rhee. Instead, the true breakthrough lies in next-generation platforms giving practitioners the data and visibility they need to do their best work, he says, adding: “By turning the days between sessions into an active, supported part of the healing process, clinician-guided technology can help assure that more people stay in care, build resilience and experience lasting well-being.” Featured Image Type of Content Article

Oct 12 · 18:033BL Media
Biotech & pharma

SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug-Coated Balloons in Complex Coronary Disease

LUCERNE, Switzerland and NEW DELHI, Oct. 12, 2026 -- The SPARX Global Randomized Controlled Trial (RCT) has been officially initiated, marking the launch of the multinational randomized trial evaluating a drug-coated balloon (DCB)-first strategy against contemporary...

Oct 12 · 18:02PR Newswire
Biotech & pharma

Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES, Oct. 12, 2026/PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Aardvark Therapeutics, Inc. IF YOU SUFFERED A LOSS ON YOUR AARDVARK THERAPEUTICS, INC. INVESTMENTS,...

Oct 12 · 18:00PR Newswire
Healthcare · Biotech & pharma

UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky

A securities class action names Unicycive Therapeutics' Chief Executive Officer and Chief Financial Officer as individual defendants under Section 20(a) control person claims, alleging they controlled disclosures telling shareholders a third-party manufacturer had made "significant progress" toward FDA compliance that the Company had never verified through its own inspection A securities class action names Unicycive Therapeutics' Chief Executive Officer and Chief Financial Officer as individual defendants under Section 20(a) control person claims, alleging they controlled disclosures telling shareholders a third-party manufacturer had made "significant progress" toward FDA compliance that the Company had never verified through its own inspection

Oct 12 · 17:49GlobeNewswire
Food & drink · Biotech & pharma

LEAD TECH Turns Booth LU-8931 into a Working Production Line at Pack Expo 2026, Demonstrating CIJ and UV Laser Coding on a Live Conveyor System

The Continuous Inkjet Printer and UV Laser Marking Machine Manufacturer Behind 70,000+ Global Installations Invites Food, Beverage, and Pharmaceutical Manufacturers to See Both Systems Run at Production Speed at Booth LU-8931, Chicago, October 18–21 CHICAGO, Oct. 12, 2026 --...

Oct 12 · 15:00PR Newswire
Biotech & pharma

Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway Analysis

MitoCareX expands its internal bioinformatics expertise to broaden the analysis of disease biology within its computational drug-discovery activities

Oct 12 · 12:07GlobeNewswire
Biotech & pharma

Accord BioPharma Launches FILKRI™ (filgrastim-laha); Now Offers Both Long- and Short-Acting G-CSF Options

FILKRI is available with a permanent Q-code, standardizing the billing and reimbursement process across all sites of care. RALEIGH, N.C., Oct. 12, 2026 -- Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology,...

Oct 12 · 12:05PR Newswire
Healthcare · Biotech & pharma

Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026

Five presentations connect targeted intestinal exposure and sustained systemic drug exposure with PDE4 target engagement and early clinical activity, supporting ongoing Phase 2 development

Oct 12 · 12:05GlobeNewswire
Biotech & pharma

Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C

Additional presentations highlight the design of an ongoing Phase 3 study evaluating tenapanor in chronic idiopathic constipation and the impact of IBS-C symptom burden on quality of life Additional presentations highlight the design of an ongoing Phase 3 study evaluating tenapanor in chronic idiopathic constipation and the impact of IBS-C symptom burden on quality of life

Oct 12 · 12:01GlobeNewswire
Finance · Healthcare

Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway

LAVAL, QC, Oct. 12, 2026 -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), announced results from a multicenter pilot study evaluating a standardized clinical pathway for cirrhosis management...

Oct 12 · 12:00PR Newswire
Industrial · Biotech & pharma

Global RNA Drugs Market Strategic Outlook, 2021-2031: Delivery, Value Chain, and Competition | 13%-15% CAGR Unlocks Pipeline and Manufacturing Opportunities

"RNA Drugs Market Strategic Analysis: Delivery Innovations, Value Chain, and Competitive Dynamics" has been added to ResearchAndMarkets.com's offering.

Oct 12 · 09:15GlobeNewswire
Biotech & pharma

Global Oligonucleotide Synthesis Market Forecast to 2031 | Market to Reach US$32.72 Billion at 17.4% CAGR as RNA Therapeutics and Molecular Diagnostics Scale

"Oligonucleotide Synthesis Market: Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering.

Oct 12 · 09:14GlobeNewswire